Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sexual dimorphism in the association of circulating TAM receptors-ligands with MASLD-related fibrosis.

JHEP reports : innovation in hepatology·2026
Same author

Erratum to 'Hot and cold fibrosis: The role of serum biomarkers to assess immune mechanisms and ECM-cell interactions in human fibrosis' [J Hepatol 83 (2025) 239-257].

Journal of hepatology·2026
Same author

Selective targeting of endothelial and perivascular angiocrine ROCK2 treats liver fibrosis.

Cell·2026
Same author

Cannabinoid receptor 2 activating antibodies: A promising therapeutic strategy for macrophage-driven fibro-inflammatory diseases.

Molecular pharmacology·2026
Same author

Scar-associated endothelial-stellate cellular crosstalk drives fibrosis resolution in MASH.

Cell reports·2026
Same author

Anti-FAP CAR T cells produced in vivo reduce fibrosis and restore liver homeostasis in metabolic dysfunction-associated steatohepatitis.

Science translational medicine·2026
Same journal

Anti-fibrotic therapy in Crohn's disease: hype or reality-can intestinal fibrosis be targeted effectively?

Expert review of gastroenterology & hepatology·2026
Same journal

Management of gastric varices: treatment options and opportunities to improve outcomes.

Expert review of gastroenterology & hepatology·2026
Same journal

Microbial ecology and hepatocellular carcinoma: should a subset be viewed as a microbiome-conditioned malignancy?

Expert review of gastroenterology & hepatology·2026
Same journal

FAPI PET in inflammatory bowel disease: a novel window on fibroblast activity, with unanswered clinical questions.

Expert review of gastroenterology & hepatology·2026
Same journal

Lyon Consensus 2.0: what has changed for GERD diagnosis?

Expert review of gastroenterology & hepatology·2026
Same journal

Proton pump inhibitors in children: indications and safety.

Expert review of gastroenterology & hepatology·2026
See all related articles

Related Experiment Video

Updated: Jun 27, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Advances in antifibrotic therapy.

Zahra Ghiassi-Nejad1, Scott L Friedman

  • 1Division of Liver Diseases, Box 1123, Mount Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029, USA. zahra.ghiassi-nejad@mssm.edu

Expert Review of Gastroenterology & Hepatology
|December 19, 2008
PubMed
Summary
This summary is machine-generated.

Developing new therapies for hepatic fibrosis is progressing well, but clinical trial endpoints remain a challenge. Emerging antifibrotic agents target liver injury and activated stellate cells, offering new hope for fibrotic liver disease.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Related Experiment Videos

Last Updated: Jun 27, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Area of Science:

  • Hepatology
  • Molecular Biology
  • Pharmacology

Background:

  • Significant advancements in understanding hepatic fibrosis pathophysiology provide a framework for antifibrotic therapy development.
  • The primary obstacle to clinical translation of antifibrotic treatments is the lack of clear clinical trial and treatment endpoints.
  • Numerous therapeutic agents, both repurposed and novel, are advancing through clinical trials for hepatic fibrosis.

Purpose of the Study:

  • To review the current landscape of emerging antifibrotic therapies for hepatic fibrosis.
  • To classify novel therapeutic agents based on their molecular targets.
  • To highlight the potential of these agents for patients with fibrotic liver disease.

Main Methods:

  • Literature review of preclinical and clinical studies on antifibrotic therapies.
  • Analysis of therapeutic targets, focusing on hepatic injury and activated hepatic stellate cells.
  • Classification of emerging agents based on their mechanisms of action.

Main Results:

  • Most antifibrotic agents in development target either hepatic injury or activated hepatic stellate cells and myofibroblasts.
  • Activated stellate cells are identified as key producers of extracellular matrix proteins.
  • A classification system based on targeting injury or stellate cell activation emerges.

Conclusions:

  • The development of antifibrotic therapies is robust, with numerous agents in clinical trials.
  • Clarifying clinical trial endpoints is crucial for advancing these promising treatments.
  • Targeting hepatic injury and stellate cell activation represents a promising therapeutic strategy for fibrotic liver disease.